Oramed Pharmaceuticals Inc. ORMP
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Oramed Pharmaceuticals Inc. (ORMP) is a healthcare company listed in the US with a market value of about $161M.
Its overall Stock Analiz score is 1.6 out of 5 (weak). The strongest part is value (3/5); the weakest is future growth (0/5).
Key numbers: a P/E of 0.9, a 5-year average ROIC of -11%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 97% below the current price.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $641000 in 2016 to $3M in 2022, growth of about 27.1% a year. It was profitable in 2 of the last 10 years in our data. Its share count rose by 9% over three years (dilution for shareholders).
Score: 1.6 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- PEG below 1.5
- 5-year EPS growth above 10% a year
- ROE above 15%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
- Pays a dividend
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $3M | $3M | $3M | $3M | $2M | $2M | $641000 |
| Net income | $64M | -$19M | $5M | -$37M | -$23M | -$12M | -$14M | -$13M | -$10M | -$11M |
| Free cash flow | -$9M | -$8M | -$11M | -$28M | -$22M | -$13M | -$13M | -$15M | -$6M | $5M |
| EPS (diluted) | $1.50 | $-0.48 | $0.14 | $-0.94 | $0.78 | $0.56 | $0.82 | $0.86 | $0.79 | $0.87 |
| Net margin | — | — | — | -1352.6% | -850.5% | -424.8% | -531.1% | -519.7% | -426.7% | -1710.5% |
| ROIC | -6.4% | -6.9% | -5.8% | -21.0% | -16.5% | -28.2% | -39.6% | -25.1% | -44.2% | -30.2% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 1 analysts is $7.00, 89% above the current price; targets range from $7.00 to $7.00; the consensus rating is “none”; expected EPS is $4.47 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Oramed Pharmaceuticals’s P/E ratio?
About 0.9, based on the last twelve months of diluted earnings per share (forward P/E about 0.8).
Is Oramed Pharmaceuticals stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 97% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Oramed Pharmaceuticals pay a dividend?
Yes. The dividend yield is about 6.78%, and it has paid dividends for 1 years in our data.
Is Oramed Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. Oramed Pharmaceuticals scores 1.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.